Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

BROOKLYN

- PMLiVE

NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

- PMLiVE

NewAmsterdam shares positive phase 3 results for CETP inhibitor obicetrapib in HeFH

Heterozygous familial hypercholesterolaemia affects approximately one in 250 people globally

- PMLiVE

Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

- PMLiVE

NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement

The agreement will provide the Dutch biotech with additional resources for its cholesterol-lowering drug candidate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links